Evidence map›Paper›PMID 21900891›Full record

GuidelineClinical pharmacology and therapeutics2011

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed and 4 more

Registry-linked trialAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01006733 (Genetics Informatics Trial), which is not on this map. Cited by 289 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
289citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01006733 phase3completednot on this map

Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis (DVT)

TypeinterventionalSponsorWashington University School of MedicineRan2011 to 2016Enrolled1,598ConditionsThromboembolismArmsPharmacogenetic, Target INR 1.8
3 · Its place in the literature

Who cites it

289 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Influence ofCardiovascular therapeutics · 2021
    Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Trial
  11. Trial
  12. Low-frequency variants at thePharmacogenomics · 2019
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2015
    Trial
  20. Review

229 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

J A JohnsonDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA. Johnson@cop.ufl.edu
L Gong
M Whirl-Carrillo
B F Gage
S A Scott
C M Stein
J L Anderson
S E Kimmel
M T M Lee
M Pirmohamed
M Wadelius
T E Klein
R B Altman
Clinical Pharmacogenetics Implementation Consortium

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
THE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2009
$24.0M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
PREDICTORS OF ANTICOAGULATION CONTROL ON WARFARINR01HL066176 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KIMMEL, STEPHEN E. · 2001 to 2012
$7.3M
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVTR01HL097036 · NHLBI · WASHINGTON UNIVERSITY · PI GAGE, BRIAN F · 2009 to 2015
$5.0M
Mount Sinai Institutes for Clinical and Translational SciencesKL2RR029885 · NCRR · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MURPHY, BARBARA T. · 2009 to 2011
$1.8M
NCRR NIH HHS KL2 RR029885NCRR NIH HHS RR029885NHLBI NIH HHS R01 HL066176NHLBI NIH HHS R01 HL097036NIGMS NIH HHS R24 GM061374NIGMS NIH HHS U01 GM061374NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ~50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb.org based on new developments in the field.(1).

Indexed as

AnticoagulantsAryl Hydrocarbon HydroxylasesCytochrome P-450 CYP2C9Dose-Response Relationship, DrugGenetic VariationGenotypeHumansMixed Function OxygenasesPharmacogeneticsVitamin K Epoxide ReductasesWarfarinAnticoagulantsAryl Hydrocarbon HydroxylasesCYP2C9 protein, humanCytochrome P-450 CYP2C9Mixed Function OxygenasesVitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID21900891
PMCPMC3187550

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.